Abstract
Together with anandamide, 2-arachidonoylglycerol (2-AG) constitutes one of the main representatives of a family of endogenous lipids known as endocannabinoids. These act by binding to CB1 and CB2 cannabinoid receptors, the molecular target of the psychoactive compound Δ9-THC, both in the periphery and in the central nervous system, where they behave as retrograde messengers to modulate synaptic transmission. These last years, evidence has accumulated to demonstrate the lead role played by the monoacylglycerol lipase (MAGL) in the regulation of 2-arachidonoylglycerol (2-AG) levels. Considering the numerous physiological functions played by this endocannabinoid, MAGL is now considered a promising target for therapeutics, as inhibitors of this enzyme could reveal useful for the treatment of pain and inflammatory disorders, as well as in cancer research, among others. Here we review the milestones that punctuated MAGL history, from its discovery to recent advances in the field of inhibitors development. An emphasis is given on the recent elucidation of the tridimensional structure of the enzyme, which could offer new opportunities for rational drug design.
Keywords: 2-arachidonoylglycerol, endocannabinoid system, monoacylglycerol lipase, monoglyceride lipase, inhibitor
Current Medicinal Chemistry
Title: A Review on the Monoacylglycerol Lipase: At the Interface Between Fat and Endocannabinoid Signalling
Volume: 17 Issue: 24
Author(s): G. Labar, J. Wouters and D.M. Lambert
Affiliation:
Keywords: 2-arachidonoylglycerol, endocannabinoid system, monoacylglycerol lipase, monoglyceride lipase, inhibitor
Abstract: Together with anandamide, 2-arachidonoylglycerol (2-AG) constitutes one of the main representatives of a family of endogenous lipids known as endocannabinoids. These act by binding to CB1 and CB2 cannabinoid receptors, the molecular target of the psychoactive compound Δ9-THC, both in the periphery and in the central nervous system, where they behave as retrograde messengers to modulate synaptic transmission. These last years, evidence has accumulated to demonstrate the lead role played by the monoacylglycerol lipase (MAGL) in the regulation of 2-arachidonoylglycerol (2-AG) levels. Considering the numerous physiological functions played by this endocannabinoid, MAGL is now considered a promising target for therapeutics, as inhibitors of this enzyme could reveal useful for the treatment of pain and inflammatory disorders, as well as in cancer research, among others. Here we review the milestones that punctuated MAGL history, from its discovery to recent advances in the field of inhibitors development. An emphasis is given on the recent elucidation of the tridimensional structure of the enzyme, which could offer new opportunities for rational drug design.
Export Options
About this article
Cite this article as:
Labar G., Wouters J. and Lambert D.M., A Review on the Monoacylglycerol Lipase: At the Interface Between Fat and Endocannabinoid Signalling, Current Medicinal Chemistry 2010; 17 (24) . https://dx.doi.org/10.2174/092986710791859414
DOI https://dx.doi.org/10.2174/092986710791859414 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interactions of Curcumin and Its Derivatives with Nucleic Acids and their Implications
Mini-Reviews in Medicinal Chemistry Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders
Current Drug Targets Protective Substances Against Zinc-Induced Neuronal Death after Ischemia:Carnosine as a Target for Drug of Vascular Type of Dementia
Recent Patents on CNS Drug Discovery (Discontinued) Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Cargo-Delivery Platforms for Targeted Delivery of Inhibitor Cargos Against Botulism
Current Topics in Medicinal Chemistry Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets γ-AApeptides as a New Strategy for Therapeutic Development
Current Medicinal Chemistry TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Enhanced Free Radical Status of Cancer Cells Success and Failure of Prooxidant/Antioxidant Treatment
Current Signal Transduction Therapy Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Tyrosol as a Neuroprotector: Strong Effects of a “Weak” Antioxidant
Current Neuropharmacology Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design Anticancer Therapeutic Strategies Based on CDK Inhibitors
Current Pharmaceutical Design The Role of RNA Modifications and RNA-modifying Proteins in Cancer Therapy and Drug Resistance
Current Cancer Drug Targets Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research Recent Advances in Targeted Anti-Vasculature Therapy: The Neuroblastoma Model
Current Drug Targets The DREAM of Pain Relief
Current Rheumatology Reviews